Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00).

Détails

ID Serval
serval:BIB_06370A2C65A1
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00).
Périodique
Annals of Oncology
Auteur(s)
Perey L., Paridaens R., Hawle H., Zaman K., Nolé F., Wildiers H., Fiche M., Dietrich D., Clément P., Köberle D., Goldhirsch A., Thürlimann B.
ISSN
0923-7534
Statut éditorial
Publié
Date de publication
2007
Peer-reviewed
Oui
Volume
18
Numéro
1
Pages
64-69
Langue
anglais
Résumé
BACKGROUND: The aim of this study was to evaluate the efficacy and tolerability of fulvestrant, an estrogen receptor antagonist, in postmenopausal women with hormone-responsive tumors progressing after aromatase inhibitor (AI) treatment. PATIENTS AND METHODS: This is a phase II, open, multicenter, noncomparative study. Two patient groups were prospectively considered: group A (n=70) with AI-responsive disease and group B (n=20) with AI-resistant disease. Fulvestrant 250 mg was administered as intramuscular injection every 28 (+/-3) days. RESULTS: All patients were pretreated with AI and 84% also with tamoxifen or toremifene; 67% had bone metastases and 45% liver metastases. Fulvestrant administration was well tolerated and yielded a clinical benefit (CB; defined as objective response or stable disease [SD] for >or=24 weeks) in 28% (90% confidence interval [CI] 19% to 39%) of patients in group A and 37% (90% CI 19% to 58%) of patients in group B. Median time to progression (TTP) was 3.6 (95% CI 3.0 to 4.8) months in group A and 3.4 (95% CI 2.5 to 6.7) months in group B. CONCLUSIONS: Overall, 30% of patients who had progressed following prior AI treatment gained CB with fulvestrant, thereby delaying indication to start chemotherapy. Prior response to an AI did not appear to be predictive for benefit with fulvestrant.
Mots-clé
Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Hormonal, Aromatase Inhibitors, Breast Neoplasms, Disease Progression, Drug Resistance, Neoplasm, Estradiol, Estrogen Receptor Modulators, Female, Humans, Middle Aged, Neoplasms, Hormone-Dependent, Postmenopause, Receptors, Estrogen, Salvage Therapy, Treatment Outcome
Pubmed
Web of science
Création de la notice
28/04/2008 8:26
Dernière modification de la notice
03/03/2018 13:25
Données d'usage